Advertisement


Linda R. Mileshkin, MBBS, MD, on Cervical Cancer: Adjuvant Chemotherapy After Chemoradiation

2021 ASCO Annual Meeting

Advertisement

Linda R. Mileshkin, MBBS, MD, of the Peter MacCallum Cancer Centre, discusses phase III findings from the OUTBACK trial, which showed that adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer did not improve either overall or progression-free survival (Abstract LBA3).



Related Videos

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Martin Reck, MD, PhD, of LungenClinic, discusses a 2-year update of the CheckMate 9LA study, which sought to determine whether nivolumab plus ipilimumab combined with two cycles of chemotherapy is more effective than four cycles of chemotherapy alone as a first-line treatment for patients with stage IV non–small cell lung cancer (Abstract 9000).

Lung Cancer

Vamsidhar Velcheti, MD, on NSCLC: Sotorasib in KRAS-Mutated Disease

Vamsidhar Velcheti, MD, of New York University, discusses overall survival and exploratory subgroup analyses from the phase II CodeBreaK 100 trial, which evaluated the use of sotorasib in pretreated KRAS G12C–mutant non–small cell lung cancer (Abstract 9003).

Multiple Myeloma

Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the outcome of a trial that explored maintenance therapy with ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Toxicities unrelated to the maintenance treatment forced the trial to close prematurely (Abstract 7003).

Leukemia
Immunotherapy

Bijal D. Shah, MD, on CLL: CAR T-Cell Therapy With Brexucabtagene Autoleucel

Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses phase II results of the ZUMA-3 study, which evaluated brexucabtagene autoleucel (KTE-X19), an anti-CD19 CAR T-cell therapy, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (Abstract 7002).

Lung Cancer
Issues in Oncology

Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment

Debora S. Bruno, MD, of Seidman Cancer Center at Cleveland Medical Center, discusses study findings that show Black patients with advanced or metastatic non–small cell lung cancer tend to be less likely to undergo biomarker testing or to be treated in clinical trials than White patients. Recommended broad-based testing, says Dr. Bruno, may help ensure equal access to quality care and clinical trials (Abstract 9005).

Advertisement

Advertisement




Advertisement